ENGLISH
CBS2017
Previous Next
Home < 科学研究

搜索结果

数量：1763 条

排序

Refine search

Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction

Clinical Trial | By Smits PC, Abdel-Wahab M, Compare-Acute Investigators et al.

BACKGROUND - In patients with ST-segment elevation myocardial infarction (STEMI), the use of percutaneous coronary intervention (PCI) to restore blood flow in an infarct-related coronary artery improves outcomes. The use of PCI in non-infarct-related coronary arteries remains controversial. METHODS - We randomly assigned 885 patients with STEMI and multivessel disease who had undergone primary PCI...

Fractional Flow Reserve-Guided Complete Revascularization Improves the Prognosis in Patients With ST-Segment-Elevation Myocardial Infarction and Severe Nonculprit Disease: A DANAMI 3-PRIMULTI Substudy (Primary PCI in Patients With ST-Elevation Myocardial Infarction and Multivessel Disease: Treatment

Original Research | By Lønborg J, Engstrøm T, DANAMI 3-PRIMULTI Investigators et al.

BACKGROUND - The impact of disease severity on the outcome after complete revascularization in patients with ST-segment-elevation myocardial infarction and multivessel disease is uncertain. The objective of this post hoc study was to evaluate the impact of number of diseased vessel, lesion location, and severity of the noninfarct-related stenosis on the effect of fractional flow reserve-guided complete revascularization. ...

2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infa

Guideline | By Levine GN, Bates ER, Blankenship JC et al.

Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial

Clinical Trial | By Engstrøm T, Kelbæk H, DANAMI-3—PRIMULTI Investigators et al.

BACKGROUND - Patients with acute ST-segment elevation myocardial infarction (STEMI) and multivessel coronary disease have a worse prognosis compared with individuals with single-vessel disease. We aimed to study the clinical outcome of patients with STEMI treated with fractional flow reserve (FFR)-guided complete revascularisation versus treatment of the infarct-related artery only. METHODS...

Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial

Clinical Trial | By Gershlick AH, Khan JN, Kelly DJ et al.

Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association

Perspective | By LY Chen, MK Chung, LA Allen et al.

Good response to tolvaptan shortens hospitalization in patients with congestive heart failure

Clinical Trial | By Kogure T, Jujo K, Hamada K et al.

Tolvaptan has been gradually spread to use as a potent diuretic for congestive heart failure in the limited country. However, the response to this aquaretic drug still is unpredictable. A total of 92 patients urgently hospitalized due to congestive heart failure and treated with tolvaptan in addition to standard treatment was retrospectively analyzed. Responder of tolvaptan treatment was defined as a patient with peak negative fluid balance greater th...

Restenosis, Stent Thrombosis, and Bleeding Complications - Navigating Between Scylla and Charybdis

Review Article | By J Torrado, L Buckley, A Durán et al.

The field of interventional cardiology has significantly evolved over 40 years by overcoming several challenges. The introduction of first-generation drug-eluting stents significantly reduced the rates of restenosis, but at the expense of an increase of late stent thrombosis. Prolonged antithrombotic therapy reduced rates of stent thrombosis, but at the cost of increased bleeding. Although the advent of second-generation drug-eluting stents subsequently re...

Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery

Review Article | By Bellinger AM, Arteaga CL, Moslehi JJ et al.

Cardio-oncology (the cardiovascular care of cancer patients) has developed as a new translational and clinical field based on the expanding repertoire of mechanism-based cancer therapies. Although these therapies have changed the natural course of many cancers, several may also lead to cardiovascular complications. Many new anticancer drugs approved over the past decade are "targeted" kinase inhibitors that interfere with intracellular signaling contrib...

Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Clinical Trial | By Catino AB, Hubbard RA, Ky B et al.

BACKGROUND - Sunitinib, used widely in metastatic renal cell carcinoma, can result in hypertension, left ventricular dysfunction, and heart failure. However, the relationships between vascular function and cardiac dysfunction with sunitinib are poorly understood. METHODS AND RESULTS - In a multicenter prospective study of 84 metastatic renal cell carcinoma patients, echocardiography, arterial tonometry, and ...

By Article Type

Original Research 785
Review Article 294
Clinical Case Study 28
Clinical Trial 415
Perspective 9
Guideline 50

By Year

2018 3
2017 2
2016 1
2015 2
0 2

By Journal

N Engl J Med. 1
Lancet. 1
J Am Coll Cardiol. 1
J Am Coll Cardiol. 2
Heart Vessels. 1
Circulation 2
Circ Heart Fail. 1
Circ Cardiovasc Interv. 1

Limit By

Title
Content
|<<... 22 23 24 25 26 27 28 ...>>|
↑BACK TO TOP

左主干暨冠状动脉分叉病变峰会

南京市心血管医院丨南京市第一医院丨南京医科大学

长乐路68号丨210006丨中国 · 南京

Copyright ⓒ CBSMD Nanjing China. All rights reserved.

关于境内代表注册有疑问请联系彭红娟、徐海梅老师

+86 - 139 138 954 77 丨 +86 - 139 147 368 46 丨 cbsnj@cbsmd.org

关于境外代表注册有疑问请联系林玲老师

+86 - 139 518 845 96 丨 cbsnj@cbsmd.org

关于学术征集有疑问请联系赵莹莹女士

+86 138 154 085 17 丨 sub@cbsmd.org